Stocks surged after a report said a
Gilead Sciences drug showed some effectiveness in treating the coronavirus, giving investors some hope there could be a treatment solution that helps the country reopen faster from the widespread shutdowns that have plunged the economy into a recession.
The
Dow Jones Industrial Average jumped 500 points, or more than 2%, and was on pace for its first close above 24,000 for the first time since March 10. The
S&P 500 traded 1.8% while the
Nasdaq Composite advanced 0.9%.
The moves put the S&P 500 on track for its first back-to-back weekly gains since early February. The S&P 500 has risen 2.3%, while the Nasdaq Composite climbed 5.8%, lifted by double-digit gains in Amazon and Netflix. The 30-stock Dow was up about 1.5% this week.
A jump in Boeing shares and a rollout Thursday evening of the White House plan to reopen the economy also added to the bullish tone on Friday.
Gilead shares jumped more than 10% after
STAT news reported that a
Chicago hospital treating coronavirus patients with remdesivir in a trial were recovering rapidly from severe symptoms. The publication cited a video it obtained where the trial results were discussed.
“An effective treatment is a huge deal and would create a path to open the economy and resume normal ‘social activities’ way sooner than a vaccine,” said Tom Lee, head of research at Fundstrat Global Advisors. “A treatment is safer and more scalable because it is only given to people who need to be treated.”
Other studies have shown remdesivir to be an effective treatment against the coronavirus. However, they have been smaller in scale. Gilead itself also cautioned that anecdotal reports are not enough to determine yet whether the drug will be an effective treatment.
Still, CNBC’s Jim Cramer said the drug could give the economy a “fighting chance.”
“Remdesivir sounds like something that can get people out of hospitals quickly,” Cramer said in a tweet Thursday. “That allows our economy to have a fighting chance..I think that remdesivir would cut the morbidity ... which would change how quickly we can open... and what we can do.”